Specialities

Specialities

Alzheimer's Disease and Dementia
Brain Trauma
COVID-19
Epilepsy
Headache Disorders
Neurodegenerative Diseases
Movement Disorders
Multiple Sclerosis
Neuroimmunology
Neurological Oncology
Neurometabolic Disease
Neuromuscular Diseases
Neuropathic Pain
Stroke
Neurosurgery
Paediatric Neurology
Parkinson's Disease
Psychiatric Disorders
Rare Diseases
Sleep Disorders
Central Nervous Disorders
Neuroradiology
Search

Trending Topic
22 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

A Review of Hyaluronidase-facilitated Subcutaneous Immunoglobulin 10% as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Robert D Hadden, Henning Andersen, Michal Bar

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare, autoimmune neurological disorder in which peripheral nerve demyelination typically results in weakness, impaired limb sensation, fatigue and pain.1–4 CIDP may adversely affect activities of daily living, with a substantial impact on functional ability and psychological well-being.2–6 Primary treatment goals are reducing symptoms, improving functional status and maintaining long-term remission.7 The […]

touchREVIEWS in Neurology. 2025;21(1):Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
Movement Disorders Parkinson's Disease
2 mins

Advances in Therapeutic Options for Gait and Balance in Parkinson’s Disease

Nicolaas I Bohnen, Roger L Albin, Martijn LTM Müller, Kelvin L Chou
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Jun 27th 2012 European Neurological Review, 2012;7(3):160-8 DOI: http://doi.org/10.17925/ENR.2012.07.03.160
Select a Section…
1

Abstract

Overview

There is a need to explore non-dopaminergic approaches to treating balance and gait problems in Parkinson’s disease (PD). There is emerging evidence on the role of cholinergic denervation of the pedunculopontine nucleus (PPN) thalamus system and falls in PD. Preliminary clinical trial data suggest that the subgroup of PD patients with frequent falls may be suitable candidates for future cholinergic augmentation clinical trials. Recent controlled clinical trials using methylphenidate have been unable to confirm earlier reports of improved gait in PD. Although progressive deterioration of axial motor symptoms occur with deep brain stimulation of the subthalamic nucleus or globus pallidus interna, new preliminary research suggests that other surgical stimulation sites, such as the PPN, may have a potential benefit on gait and balance impairments in PD. Continuing vigorous exercise and physical fitness should be highly encouraged to patients with PD who are at risk of physical deconditioning and fear of falling, but effective antifall physical therapy interventions remain an unmet clinical need.

Keywords

Acetylcholine, dopamine, noradrenergic, deep brain stimulation, exercise, falls, mobility, Parkinson’s disease, pedunculopontine nucleus, striatum, substantia nigra

2

Article

Parkinson’s disease (PD) is a clinical syndrome consisting of a variable combination of the four cardinal features of resting tremor, rigidity, bradykinesia and postural instability.1 Akinesia, defined as inability to initiate movement (e.g. gait ignition failure) or sustain movement (e.g. sudden freezes), is considered by some to be the fifth cardinal feature of PD.2 Most motor features of PD are believed to result mainly from loss of striatal dopamine secondary to the degeneration of dopaminergic neurons of the substantia nigra pars compacta (SNpc).3 The greater the neuronal loss in the SNpc, the lower the striatal dopamine concentration and the more severe the parkinsonian symptoms, particularly bradykinesia.4 The rate of disease progression is highly variable among PD patients. Patients with tremor-predominant disease at onset, for example, tend to progress more slowly than patients with early prominent postural instability and gait disturbances (PIGD).5

Clinical characteristics of parkinsonian locomotor patterns include slow gait and reduced angular excursion of joints such as shoulder, knee and trunk joints.6,7 With disease progression, stooped posture, short steps and shuffling (the latter associated with reduced ground clearance and festination) become more prominent features.7–9 Falls are common in PD. Unlike falls in the general population, which result generally from slipping or tripping incidents, the majority of falls in PD occur during routine walking, stopping, turning and standing up or bending down manoeuvres.10,11 One prospective survey of relatively mildly affected PD patients found that 60 % fell during a six-month period and 33 % had multiple falls in this period.12 Fall risk in PD is a bell-shaped function of disease severity,13 reaching a maximum during Hoehn and Yahr stage 3 and decreasing in later stages as patients become less mobile.14,15 The emergence of postural instability marks the onset of increased risk for severe disability in PD patients as up to 40 % of patients with postural instability have multiple falls which may result in injury, including potentially crippling hip and wrist fractures.16

To view the full article in PDF or eBook formats, please click on the icons above.

2

References

  1. Quinn N, Parkinsonism-recognition and differential diagnosis,
    BMJ, 1995;310:447–52.

  2. Factor SA, The clinical spectrum of freezing of gait in atypical
    parkinsonism, Mov Disord, 2008;23(Suppl. 2):S431–8.

  3. Hughes AJ, Daniel SE, Blankson S, Lees AJ, A clinicopathologic
    study of 100 cases of Parkinson’s disease, Arch Neurol,
    1993;50:140–8.

  4. Bernheimer H, Birkmayer W, Hornykiewicz O, et al., Brain
    dopamine and the syndromes of Parkinson and Huntington.
    Clinical, morphological and neurochemical correlations,
    J Neurol Sci, 1973;20:415–55.

  5. Post B, Merkus MP, de Haan RJ, Speelman JD, Prognostic
    factors for the progression of Parkinson’s disease: a
    systematic review, Mov Disord, 2007;22:1839–51; quiz 1988.

  6. Azulay JP, Van Den Brand C, Mestre D, et al., [Automatic
    motion analysis of gait in patients with Parkinson
    disease: effects of levodopa and visual stimulations],
    Rev Neurol (Paris), 1996;152:128–34. Article in French.

  7. Kemoun G, Defebvre L, [Clinical description, analysis of
    posture, initiation of stabilized gait], Presse Med,
    2001;30:452–9. Article in French.

  8. Murray MP, Sepic SB, Gardner GM, Downs WJ, Walking
    patterns of men with parkinsonism, Am J Phys Med,
    1978;57:278–94.

  9. Nieuwboer A, Dom R, De Weerdt W, et al., Abnormalities of
    the spatiotemporal characteristics of gait at the onset of
    freezing in Parkinson’s disease, Mov Disord, 2001;16:1066–75.

  10. Bloem BR, Grimbergen YA, Cramer M, et al., Prospective
    assessment of falls in Parkinson’s disease, J Neurol,
    2001;248:950–8.

  11. Morris ME, Movement disorders in people with Parkinson
    disease: a model for physical therapy, Phys Ther, 2000;80:578–97.

  12. Bloem BR, Grimbergen YAM, Cramer M, et al., Prospective
    assessment of falls in Parkinson’s disease, Mov Disord,
    1998;10:147.

  13. Pickering RM, Mazibrada G, Wood BH, et al., A meta-analysis
    of six prospective studies of falls in Parkinson’s disease, Mov
    Disord, 2004;19:S262.

  14. Bloem BR, van Vugt JP, Beckley DJ, Postural instability and
    falls in Parkinson’s disease, Adv Neurol, 2001;87:209–23.

  15. Wood BH, Bilclough JA, Bowron A, Walker RW, Incidence and
    prediction of falls in Parkinson’s disease: a prospective
    multidisciplinary study, J Neurol Neurosurg Psychiatry, 2002;72:721–5.

  16. Gray P, Hildebrand K, Fall risk factors in Parkinson’s disease,
    J Neurosci Nurs, 2000;32:222–8.

  17. Bohnen NI, Cham R, Postural control, gait, and dopamine
    functions in parkinsonian movement disorders, Clin Geriatr Med,
    2006;22:797–812.

  18. Bowes SG, Clark PK, Leeman AL, et al., Determinants of gait in
    the elderly parkinsonian on maintenance levodopa/carbidopa
    therapy, Br J Clin Pharmacology, 1990;30:13–24.

  19. Ferrandez AM, Blin O, A comparison between the effect of
    intentional modulations and the action of L-dopa on gait in
    Parkinson’s disease, Behav Brain Res, 1991;45:177–83.

  20. O’Sullivan JD, Said CM, Dillon LC, et al., Gait analysis in
    patients with Parkinson’s disease and motor fluctuations:
    influence of levodopa and comparison with other measures
    of motor function, Mov Disord, 1998;13:900–6.

  21. Shan DE, Lee SJ, Chao LY, Yeh SI, Gait analysis in advanced
    Parkinson’s disease—effect of levodopa and tolcapone,
    Can J Neurol Sci, 2001;28:70–5.

  22. Blin O, Ferrandez AM, Pailhous J, Serratrice G, Dopa-sensitive
    and dopa-resistant gait parameters in Parkinson’s disease,
    J Neurol Sci, 1991;103:51–4.

  23. Ebersbach G, Heijmenberg M, Kindermann L, et al.,
    Interference of rhythmic constraint on gait in healthy subjects
    and patients with early Parkinson’s disease: evidence for
    impaired locomotor pattern generation in early Parkinson’s
    disease., Mov Disord, 1999;14:619–25.

  24. Rossignol S, Dubuc R, Gossard JP, Dynamic sensorimotor
    interactions in locomotion, Physiol Rev, 2006;86:89–154.

  25. Mori S, Matsui T, Kuze B, et al., Stimulation of a restricted
    region in the midline cerebellar white matter evokes
    coordinated quadrupedal locomotion in the decerebrate cat,
    J Neurophysiol, 1999;82:290–300.

  26. Shik ML, Orlovsky GN, Neurophysiology of locomotor
    automatism, Physiol Rev, 1976;56:465–501.

  27. Alexander GE, DeLong MR, Strick PL, Parallel organization of
    functionally segregated circuits linking basal ganglia and
    cortex, Annu Rev Neurosci, 1986;9:357–81.

  28. Redgrave P, Rodriguez M, Smith Y, et al., Goal-directed and
    habitual control in the basal ganglia: implications for
    Parkinson’s disease, Nat Rev Neurosci, 2010;11:760–72.

  29. Balleine BW, O’Doherty JP, Human and rodent homologies in
    action control: corticostriatal determinants of goal-directed
    and habitual action, Neuropsychopharmacology, 2010;35:48–69.

  30. Yin HH, Knowlton BJ, The role of the basal ganglia in habit
    formation, Nat Rev Neurosci, 2006;7:464–76.

  31. Latt LD, Sparto PJ, Furman JM, Redfern MS, The steady-state
    postural response to continuous sinusoidal galvanic
    vestibular stimulation, Gait Posture, 2003;18:64–72.

  32. Horak FB, Shupert CL, Dietz V, Horstmann G, Vestibular and
    somatosensory contributions to responses to head and body
    displacements in stance, Exp Brain Res, 1994;100:93–106.

  33. Mahboobin A, Loughlin PJ, Redfern MS, Sparto PJ, Sensory
    re-weighting in human postural control during moving-scene
    perturbations, Exp Brain Res, 2005;167:260–7.

  34. Visser JE, Bloem BR, Role of the basal ganglia in balance
    control, Neural Plast, 2005;12:161–74.

  35. Burleigh-Jacobs A, Horak FB, Nutt JG, Obeso JA, Step initiation
    in Parkinson’s disease: influence of levodopa and external
    sensory triggers, Mov Disord, 1997;12:206–15.

  36. Giladi N, Treves TA, Simon ES, et al., Freezing of gait in
    patients with advanced Parkinson’s disease, J Neural Transm,
    2001;108:53–61.

  37. Snijders AH, Toni I, Ruzicka E, Bloem BR, Bicycling breaks the
    ice for freezers of gait, Mov Disord, 2011;26:367–71.

  38. Kish SJ, Shannak K, Hornykiewicz O, Uneven pattern of
    dopamine loss in the striatum of patients with idiopathic
    Parkinson’s disease, N Engl J Med, 1988;318:876–80.

  39. Ouchi Y, Kanno T, Okada H, et al., Changes in dopamine
    availability in the nigrostriatal and mesocortical dopaminergic
    systems by gait in Parkinson’s disease, Brain, 2001;124:784–92.

  40. Bartels AL, de Jong BM, Giladi N, et al., Striatal dopa and
    glucose metabolism in PD patients with freezing of gait,
    Mov Disord, 2006;21:1326–32.

  41. Azulay JP, Mesure S, Amblard B, et al., Visual control of
    locomotion in Parkinson’s disease, Brain, 1999;122:111–20.

  42. Lewis GN, Byblow WD, Walt SE, Stride length regulation in
    Parkinson’s disease: the use of extrinsic, visual cues,
    Brain, 2000;123:2077–90.

  43. McIntosh GC, Brown SH, Rice RR, Thaut MH, Rhythmic
    auditory-motor facilitation of gait patterns in patients with
    Parkinson’s disease, J Neurol Neurosurg Psychiatry, 1997;62:22–6.

  44. Thaut MH, McIntosh GC, Rice RR, et al., Rhythmic auditory
    stimulation in gait training for Parkinson’s disease patients,
    Mov Dis, 1996;11:193–200.

  45. Howe TE, Lovgreen B, Cody FW, et al., Auditory cues can
    modify the gait of persons with early-stage Parkinson’s
    disease: a method for enhancing parkinsonian walking
    performance?, Clin Rehabilitation, 2003;17:363–7.

  46. Woollacott M, Shumway-Cook A, Attention and the control of
    posture and gait: a review of an emerging area of research,
    Gait Posture, 2002;16:1–14.

  47. Lundin-Olsson L, Nyberg L, Gustafson Y, ‘Stops walking
    when talking’ as a predictor of falls in elderly people,
    Lancet, 1997;349:617.

  48. Lees AJ, Smith E, Cognitive deficits in the early stages of
    Parkinson’s disease, Brain, 1983;106:257–70.

  49. Dubois B, Pillon B, Cognitive deficits in Parkinson’s disease,
    J Neurology, 1997;244:2–8.

  50. Stuss DT, Alexander MP, Executive functions and the frontal
    lobes: a conceptual view, Psychological Res, 2000;63:289–98.

  51. Bloem BR, Valkenburg VV, Slabbekoorn M, van Dijk JG, The
    multiple tasks test. Strategies in Parkinson’s disease,
    Exp Brain Res, 2001;137:478–86.

  52. Yogev G, Giladi N, Peretz C, et al., Dual tasking, gait
    rhythmicity, and Parkinson’s disease: which aspects of gait
    are attention demanding?, Eur J Neurosci, 2005;22:1248–56.

  53. Marchese R, Bove M, Abbruzzese G, Effect of cognitive and
    motor tasks on postural stability in Parkinson’s disease: a
    posturographic study, Mov Disord, 2003;18:652–8.

  54. Camicioli R, Oken BS, Sexton G, et al., Verbal fluency task
    affects gait in Parkinson’s disease with motor freezing,
    J Geriatr Psychiatry Neurology, 1998;11:181–5.

  55. Bond JM, Morris M, Goal-directed secondary motor tasks:
    their effects on gait in subjects with Parkinson disease,
    Arch Phys Med Rehabilitation, 2000;81:110–6.

  56. O’Shea S, Morris ME, Iansek R, Dual task interference during
    gait in people with Parkinson disease: effects of motor versus
    cognitive secondary tasks, Phys Ther, 2002;82:888–97.

  57. Hausdorff JM, Schaafsma JD, Balash Y, et al., Impaired
    regulation of stride variability in Parkinson’s disease subjects
    with freezing of gait, Exp Brain Res, 2003;149:187–94.

  58. Hausdorff JM, Cudkowicz ME, Firtion R, et al., Gait variability
    and basal ganglia disorders: stride-to-stride variations of gait
    cycle timing in Parkinson’s disease and Huntington’s disease,
    Mov Disord, 1998;13:428–37.

  59. Springer S, Giladi N, Peretz C, et al., Dual-tasking effects on
    gait variability: the role of aging, falls, and executive function,
    Mov Disord, 2006;21:950–7.

  60. Hausdorff JM, Balash J, Giladi N, Effects of cognitive challenge
    on gait variability in patients with Parkinson’s disease,
    J Geriatr Psychiatry Neurology, 2003;16:53–8.

  61. Jellinger K, The pedunculopontine nucleus in Parkinson’s
    disease, progressive supranuclear palsy and Alzheimer’s
    disease, J Neurol Neurosurg Psychiatry, 1988;51:540–3.

  62. Braak H, Del Tredici K, Nervous system pathology in sporadic
    Parkinson disease, Neurology, 2008;70:1916–25.

  63. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F, Neuronal
    loss in the pedunculopontine tegmental nucleus in Parkinson
    disease and in progressive supranuclear palsy,
    Proc Natl Acad Sci U S A, 1987;84:5976–80.

  64. Lee MS, Rinne JO, Marsden CD, The pedunculopontine
    nucleus: its role in the genesis of movement disorders, Yonsei
    Med J, 2000;41:167–84.

  65. Stein JF, Akinesia, motor oscillations and the
    pedunculopontine nucleus in rats and men, Exp Neurol,
    2009;215:1–4.

  66. Pahapill PA, Lozano AM, The pedunculopontine nucleus and
    Parkinson’s disease, Brain, 2000;123:1767–83.

  67. Alam M, Schwabe K, Krauss JK, The pedunculopontine
    nucleus area: critical evaluation of interspecies differences
    relevant for its use as a target for deep brain stimulation,
    Brain, 2011;134:11–23.

  68. Heckers S, Geula C, Mesulam M, Cholinergic innervation of
    the human thalamus: Dual origin and differential nuclear
    distribution, J Comp Neurol, 1992;325:68–82.

  69. Winn P, How best to consider the structure and function of
    the pedunculopontine tegmental nucleus: evidence from
    animal studies, J Neurol Sci, 2006;248:234–50.

  70. Lavoie B, Parent A, Pedunculopontine nucleus in the squirrel
    monkey: projections to the basal ganglia as revealed by
    anterograde tract-tracing methods, J Comp Neurol, 1994;344:210–31.

  71. Zweig RM, Jankel WR, Hedreen JC, et al., The
    pedunculopontine nucleus in Parkinson’s disease, Ann Neurol,
    1989;26:41–6.

  72. Gai WP, Halliday GM, Blumbergs PC, et al., Substance Pcontaining
    neurons in the mesopontine tegmentum are severely
    affected in Parkinson’s disease, Brain, 1991;114:2253–67.

  73. Karachi C, Grabli D, Bernard FA, et al., Cholinergic
    mesencephalic neurons are involved in gait and postural
    disorders in Parkinson disease, J Clin Invest, 2010;120:2745–54.

  74. Jenkinson N, Nandi D, Miall RC, et al., Pedunculopontine
    nucleus stimulation improves akinesia in a Parkinsonian
    monkey, Neuroreport, 2004;15:2621–4.

  75. Garcia-Rill E, Houser CR, Skinner RD, et al., Locomotioninducing
    sites in the vicinity of the pedunculopontine nucleus,
    Brain Res Bull, 1987;18:731–8.

  76. Hasselmo ME, Sarter M, Modes and models of forebrain
    cholinergic neuromodulation of cognition,
    Neuropsychopharmacology, 2011;36:52–73.

  77. Bohnen NI, Kaufer DI, Ivanco LS, et al., Cortical cholinergic
    function is more severely affected in parkinsonian dementia
    than in Alzheimer disease: an in vivo positron emission
    tomographic study, Arch Neurol, 2003;60:1745–8.

  78. Shimada H, Hirano S, Shinotoh H, et al., Mapping of brain
    acetylcholinesterase alterations in Lewy body disease by PET,
    Neurology, 2009;73:273–8.

  79. Bohnen NI, Albin RL, The cholinergic system and Parkinson
    disease, Behav Brain Res, 2011;221:564–73.

  80. Spuz CA, Paolone G, Briscoe S, et al., Deficits in attentional
    control of balance, mobility, and complex movements in a rat
    model of early state, multisystem Parkinson disease,
    Society for Neuroscience, Washington DC, November 2011,
    Abstract 244.02.

  81. Bohnen NI, Muller ML, Koeppe RA, et al., History of falls in
    Parkinson disease is associated with reduced cholinergic
    activity, Neurology, 2009;73:1670–6.

  82. Alves G, Larsen JP, Emre M, et al., Changes in motor subtype
    and risk for incident dementia in Parkinson’s disease,
    Mov Disord, 2006;21:1123–30.

  83. Taylor JP, Rowan EN, Lett D, et al., Poor attentional function
    predicts cognitive decline in patients with non-demented
    Parkinson’s disease independent of motor phenotype,
    J Neurol Neurosurg Psychiatry, 2008;79:1318–23.

  84. Grimbergen YA, Langston JW, Roos RA, Bloem BR, Postural
    instability in Parkinson’s disease: the adrenergic hypothesis
    and the locus coeruleus, Expert Rev Neurother, 2009;9:279–90.

  85. Moore RY, Bloom FE, Central catecholamine neuron systems:
    anatomy and physiology of the norepinephrine and
    epinephrine systems, Annu Rev Neurosci, 1979;2:113–68.

  86. Zarow C, Lyness SA, Mortimer JA, Chui HC, Neuronal loss is
    greater in the locus coeruleus than nucleus basalis and
    substantia nigra in Alzheimer and Parkinson diseases,
    Arch Neurol, 2003;60:337–41.

  87. Gunning-Dixon FM, Raz N, The cognitive correlates of white
    matter abnormalities in normal aging: A quantitative review,
    Neuropsychology, 2000;14:224–32.

  88. Pantoni L, Garcia JH, Pathogenesis of leukoaraiosis, Stroke,
    1997;28:652–9.

  89. Longstreth WT, Jr, Manolio TA, Arnold A, et al., Clinical
    correlates of white matter findings on cranial magnetic
    resonance imaging of 3301 elderly people. The
    Cardiovascular Health Study, Stroke, 1996;27:1274–82.

  90. Baezner H, Blahak C, Poggesi A, et al., Association of gait and
    balance disorders with age-related white matter changes: the
    LADIS study, Neurology, 2008;70:935–42.

  91. Murray ME, Senjem ML, Petersen RC, et al., Functional impact
    of white matter hyperintensities in cognitively normal elderly
    subjects, Arch Neurol, 2010;67:1379–85.

  92. Bohnen NI, Muller ML, Zarzhevsky N, et al., Leucoaraiosis,
    nigrostriatal denervation and motor symptoms in Parkinson’s
    disease, Brain, 2011;134:2358–65.

  93. Schneider JA, Bennett DA, Where vascular meets
    neurodegenerative disease, Stroke, 2010;41:S144–6.

  94. Chung KA, Lobb BM, Nutt JG, Horak F, Cholinergic
    augmentation in frequently fallings subjects with Parkinson’s
    disease, Mov Disord, 2009;24(Suppl. 1):S259.

  95. Ceravolo R, Volterrani D, Frosini D, et al., Brain perfusion
    effects of cholinesterase inhibitors in Parkinson’s disease
    with dementia, J Neural Transm, 2006;113:1787–90.

  96. Ahlskog JE, Think before you leap: donepezil reduces falls?,
    Neurology, 2010;75:1226–7.

  97. Montero-Odasso M, Wells J, Borrie M, Can cognitive
    enhancers reduce the risk of falls in people with dementia?
    An open-label study with controls, J Am Geriatr Soc,
    2009;57:359–60.

  98. Sarter M, Parikh V, Howe WM, nAChR agonist-induced
    cognition enhancement: integration of cognitive and neuronal
    mechanisms, Biochem Pharmacol, 2009;78:658–67.

  99. Pollak L, Dobronevsky Y, Prohorov T, et al., Low dose
    methylphenidate improves freezing in advanced Parkinson’s
    disease during off-state, J Neural Transm Suppl, 2007:145–8.

  100. Devos D, Krystkowiak P, Clement F, et al., Improvement of
    gait by chronic, high doses of methylphenidate in patients
    with advanced Parkinson’s disease, J Neurol Neurosurg
    Psychiatry, 2007;78:470–5.

  101. Auriel E, Hausdorff JM, Herman T, et al., Effects of
    methylphenidate on cognitive function and gait in patients
    with Parkinson’s disease: a pilot study, Clin Neuropharmacol,
    2006;29:15–7.

  102. Nutt JG, Carter JH, Carlson NE, Effects of methylphenidate on
    response to oral levodopa: a double-blind clinical trial,
    Arch Neurol, 2007;64:319–23.

  103. Auriel E, Hausdorff JM, Giladi N, Methylphenidate for the
    treatment of Parkinson disease and other neurological
    disorders, Clin Neuropharmacol, 2009;32:75–81.

  104. Espay AJ, Dwivedi AK, Payne M, et al., Methylphenidate for
    gait impairment in Parkinson disease: a randomized clinical
    trial, Neurology, 2011;76:1256–62.

  105. Jankovic J, Atomoxetine for freezing of gait in Parkinson
    disease, J Neurol Sci, 2009;284:177–8.

  106. Benabid AL, Pollak P, Gervason C, et al., Long-term
    suppression of tremor by chronic stimulation of the ventral
    intermediate thalamic nucleus, Lancet, 1991;337:403–6.

  107. Deuschl G, Bain P, Deep brain stimulation for tremor
    [correction of trauma]: patient selection and evaluation,
    Mov Disord, 2002;17(Suppl. 3):S102–11.

  108. Pahwa R, Lyons KE, Wilkinson SB, et al., Long-term evaluation
    of deep brain stimulation of the thalamus, J Neurosurg,
    2006;104:506–12.

  109. Bakker M, Esselink RA, Munneke M, et al., Effects of
    stereotactic neurosurgery on postural instability and gait in
    Parkinson’s disease, Mov Disord, 2004;19:1092–9.

  110. Weaver FM, Follett K, Stern M, et al., Bilateral deep brain
    stimulation vs best medical therapy for patients with
    advanced Parkinson disease: a randomized
    controlled trial, JAMA, 2009;301:63–73.

  111. Follett KA, Weaver FM, Stern M, et al., Pallidal versus
    subthalamic deep-brain stimulation for Parkinson’s disease,
    N Engl J Med, 2010;362:2077–91.

  112. Krack P, Batir A, Van Blercom N, et al., Five-year follow-up of
    bilateral stimulation of the subthalamic nucleus in advanced
    Parkinson’s disease, N Engl J Med, 2003;349:1925–34.

  113. Liang GS, Chou KL, Baltuch GH, et al., Long-term outcomes of
    bilateral subthalamic nucleus stimulation in patients with
    advanced Parkinson’s disease, Stereotact Funct Neurosurg,
    2006;84:221–7.

  114. Ostergaard K, Aa Sunde N, Evolution of Parkinson’s disease
    during 4 years of bilateral deep brain stimulation of the
    subthalamic nucleus, Mov Disord, 2006;21:624–31.

  115. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al., Bilateral deep
    brain stimulation in Parkinson’s disease: a multicentre study
    with 4 years follow-up, Brain, 2005;128:2240–9.

  116. Schupbach WM, Chastan N, Welter ML, et al., Stimulation of
    the subthalamic nucleus in Parkinson’s disease: a 5 year
    follow up, J Neurol Neurosurg Psychiatry, 2005;76:1640–4.

  117. Castrioto A, Lozano AM, Poon YY, et al., Ten-year outcome of
    subthalamic stimulation in Parkinson disease: a blinded
    evaluation, Arch Neurol, 2011;68:1550–6.

  118. St George RJ, Nutt JG, Burchiel KJ, Horak FB, A metaregression
    of the long-term effects of deep brain stimulation
    on balance and gait in PD, Neurology, 2010;75:1292–9.

  119. Moreau C, Defebvre L, Destee A, et al., STN-DBS frequency
    effects on freezing of gait in advanced Parkinson disease,
    Neurology, 2008;71:80–4.

  120. Brozova H, Barnaure I, Alterman RL, Tagliati M, STN-DBS
    frequency effects on freezing of gait in advanced Parkinson
    disease, Neurology, 2009;72:770; author reply 770–1.

  121. Brudzynski SM, Houghton PE, Brownlee RD, Mogenson GJ,
    Involvement of neuronal cell bodies of the mesencephalic
    locomotor region in the initiation of locomotor activity of
    freely behaving rats, Brain Res Bull,
    1986;16:377–81.

  122. Milner KL, Mogenson GJ, Electrical and chemical activation of
    the mesencephalic and subthalamic locomotor regions in
    freely moving rats, Brain Res, 1988;452:273–85.

  123. Plaha P, Gill SS, Bilateral deep brain stimulation of the
    pedunculopontine nucleus for Parkinson’s disease,
    Neuroreport, 2005;16:1883–7.

  124. Bacskai BJ, Frosch MP, Freeman SH, et al., Molecular imaging
    with Pittsburgh Compound B confirmed at autopsy: a case
    report, Arch Neurol, 2007;64:431–4.

  125. Ferraye MU, Debu B, Fraix V, et al., Effects of
    pedunculopontine nucleus area stimulation on gait disorders
    in Parkinson’s disease, Brain, 2010;133:205–14.

  126. Moro E, Hamani C, Poon YY, et al., Unilateral
    pedunculopontine stimulation improves falls in Parkinson’s
    disease, Brain, 2010;133:215–24.

  127. Ostrem JL, Christine CW, Glass GA, et al., Pedunculopontine
    nucleus deep brain stimulation in a patient with primary
    progressive freezing gait disorder, Stereotact Funct Neurosurg,
    2010;88:51–5.

  128. Zrinzo L, Zrinzo LV, Surgical anatomy of the pedunculopontine
    and peripeduncular nuclei, Br J Neurosurg,
    2008;22(Suppl. 1):S19–24.

  129. Khan S, Mooney L, Plaha P, et al., Outcomes from stimulation
    of the caudal zona incerta and pedunculopontine nucleus in
    patients with Parkinson’s disease, Br J Neurosurg,
    2011;25:273–80.

  130. Morris ME, Martin CL, Schenkman ML, Striding out with
    Parkinson disease: evidence-based physical therapy for gait
    disorders, Phys Ther, 2010;90:280–8.

  131. Kwakkel G, de Goede CJ, van Wegen EE, Impact of physical
    therapy for Parkinson’s disease: a critical review of the
    literature, Parkinsonism Relat Disord,
    2007;13(Suppl. 3):S478–87.

  132. Goodwin VA, Richards SH, Taylor RS, et al., The effectiveness
    of exercise interventions for people with Parkinson’s
    disease: a systematic review and meta-analysis, Mov Disord,
    2008;23:631–40.

  133. Dibble LE, Addison O, Papa E, The effects of exercise on
    balance in persons with Parkinson’s disease: a systematic
    review across the disability spectrum, J Neurol Phys Ther,
    2009;33:14–26.

  134. Allen NE, Sherrington C, Paul SS, Canning CG, Balance and
    falls in Parkinson’s disease: A meta-analysis of the
    effect of exercise and motor training, Mov Disord,
    2011;26:1605–15.

  135. Cakit BD, Saracoglu M, Genc H, et al., The effects of
    incremental speed-dependent treadmill training on postural
    instability and fear of falling in Parkinson’s disease,
    Clin Rehabil, 2007;21:698–705.

  136. Mehrholz J, Friis R, Kugler J, et al., Treadmill training for
    patients with Parkinson’s disease, Cochrane Database Syst Rev,
    2010;(1):CD007830.

  137. Hackney ME, Earhart GM, Tai Chi improves balance and
    mobility in people with Parkinson disease, Gait Posture,
    2008;28:456–60.

  138. Ridgel AL, Kim CH, Fickes EJ, et al., Changes in executive
    function after acute bouts of passive cycling in Parkinson’s
    disease, J Aging Phys Act, 2011;19:87–98.

3

Article Information

Disclosure

The authors have no conflicts of interest to declare.

Correspondence

Nicolaas I Bohnen, Functional Neuroimaging, Cognitive and Mobility Laboratory, Departments of Radiology and Neurology, University of Michigan, 24 Frank Lloyd Wright Drive, Box 362, Ann Arbor, MI 48105-9755, US. E: nbohnen@umich.edu

Support

The authors gratefully acknowledge research support from the National Institutes of Health (NIH) (National Institute of Neurological Disorders and Stroke [NINDS]), the Department of Veterans Affairs, and the Michael J Fox Foundation.

Received

2011-08-31T00:00:00

4

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Human brain left x-ray view
17 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Wearable Technologies for Parkinson’s Disease: Exploring Their Clinical Potential

Caitríona L Cox, Alistair J Mackett

Parkinson’s disease (PD) is a complex neurodegenerative condition that predominantly affects older people, with a rising prevalence worldwide.1,2 There are many on-going challenges and unmet needs in PD: difficulties in making an accurate diagnosis (particularly in the early stages of the disease), troubling side effects associated with the available pharmacological treatments, a lack of effective disease-modifying therapies […]

touchREVIEWS in Neurology. 2024;20(2):13-19
Advertisement
    • 5

    Related Content in Parkinson's Disease

    Latest articles videos and clinical updates - straight to your inbox

    Close Popup